Understanding the Nilotinib trials

Understanding the Nilotinib trials

The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.

Pin It on Pinterest